TG Therapeutics to Host Conference Call on Third Quarter 2021 Financial Results and Business Update
TG Therapeutics (NASDAQ: TGTX) will hold a conference call on November 4, 2021, at 8:30 AM ET to discuss Q3 2021 results and provide a business outlook for the remainder of the year. The call will be hosted by Michael S. Weiss, Chairman and CEO. Participants can join by calling the provided numbers, with a live webcast available on the company's website. A financial results press release will precede the call.
- TG Therapeutics has received accelerated FDA approval for UKONIQ®.
- Company has three programs in Phase 3 development.
- None.
Conference call to be held Thursday, November 4, 2021 at 8:30 AM ET
NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Thursday, November 4, 2021 at 8:30 AM ET to discuss results for the third quarter 2021 and provide a business outlook for the remainder of the year. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQ® (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has three programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.
UKONIQ® is a trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When is the TG Therapeutics Q3 2021 conference call?
How can I join the TG Therapeutics conference call?
What will TG Therapeutics discuss in the conference call?
Where can I find the webcast for the TG Therapeutics call?
